Prevention Study with Diamyd, Inc.'s Diabetes Vaccine Fully Recruited
1/9/2012 7:38:58 AM
STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical’s diabetes vaccine Diamyd®. The study is thus fully recruited. The purpose of the study is to evaluate whether preventive treatment with Diamyd® can delay or halt the progression of the disease so that the children do not develop clinical symptoms of type 1 diabetes.